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Abstract
Background: Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims N-terminally extended antigenic peptide precursors
down to mature antigenic peptides for presentation by major histocompatibility complex (MHC) class I molecules. ERAP1
has unique properties for an aminopeptidase being able to trim peptides in vitro based on their length and the nature of
their C-termini.
Methodology/Principal Findings: In an effort to better understand the molecular mechanism that ERAP1 uses to trim
peptides, we systematically analyzed the enzyme’s substrate preferences using collections of peptide substrates. We
discovered strong internal sequence preferences of peptide N-terminus trimming by ERAP1. Preferences were only found
for positively charged or hydrophobic residues resulting to trimming rate changes by up to 100 fold for single residue
substitutions and more than 40,000 fold for multiple residue substitutions for peptides with identical N-termini. Molecular
modelling of ERAP1 revealed a large internal cavity that carries a strong negative electrostatic potential and is large enough
to accommodate peptides adjacent to the enzyme’s active site. This model can readily account for the strong preference for
positively charged side chains.
Conclusions/Significance: To our knowledge no other aminopeptidase has been described to have such strong preferences
for internal residues so distal to the N-terminus. Overall, our findings indicate that the internal sequence of the peptide can
affect its trimming by ERAP1 as much as the peptide’s length and C-terminus. We therefore propose that ERAP1 recognizes
the full length of its peptide-substrate and not just the N- and C- termini. It is possible that ERAP1 trimming preferences
influence the rate of generation and the composition of antigenic peptides in vivo.
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Introduction
Antigenic peptides presented by MHC class I molecules act as a
status indicator of the cell’s condition and play a pivotal role in the
activation of T-lymphocytes versus pathogens like viruses or in
pathological conditions like cancer. Recognition of a MHC-
peptide complex by the T-cell receptor (TCR) of a cytotoxic T-
lymphocyte can lead to the activation of the T-lymphocyte and to
target cell lysis [1–4]. The antigenic peptides that are loaded on
MHC class I molecules are generally derived from intracellular
proteins after degradation by an intricate but not deeply
understood proteolytic cascade. The first step of this cascade is
considered to be the proteasome – a large cytosolic multi-subunit
proteolytic complex that is responsible for the degradation of most
intracellular proteins and plays crucial roles in the homeostasis and
regulation of many cellular processes [5–7]. The proteasome
generates fragments (peptides) of the protein it degrades that are
subjected to further proteolysis in the cytosol [8–10]. A small
subset of the peptides generated survives the proteolytic activity in
the cytosol and is actively transported to the Endoplasmic
Reticulum (ER) by a specialized peptide transporter called
Transporter Associated with Antigen Processing (TAP) [11–13].
In the ER further trimming of the peptides can occur by ER-
resident aminopeptidases before the final products are loaded onto
nascent MHC class I chains [14–19]. The mature MHC-peptide
complexes are transported via the secretory pathway to the cell
surface for presentation to T-lymphocytes. The proteasome-
generated peptides destined for MHC loading generally have the
correct C-terminus for MHC binding but carry N-terminal
extensions that need to be trimmed away [20]. This trimming is
completed in the ER although it may be initiated in the cytosol. A
slightly different version of the proteasome, termed the immuno-
proteasome, exists in immune surveillance cells like dendritic cells,
and is up-regulated by immune response modulators such as
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tended antigenic peptide precursors more efficiently than the
proteasome, something that may help the peptides survive the
proteolytic activity of the cytosol and enhance their chances to be
transported into the ER [20].
At least one ER-resident aminopeptidase now named ERAP1
(ER-AminoPeptidase 1) or ERAAP (ER aminopeptidase associat-
ed with antigen presentation) has been identified to play important
roles in the generation of mature antigenic peptides through its
action on N-terminally extended antigenic peptide precursors.
This aminopeptidase has been previously identified as A-LAP
(Adipocyte-derived leucine aminopeptidase), PILS-AP (puromy-
cin-insensitive leucyl-specific aminopeptidase) and ARTS-1 (ami-
nopeptidase regulator of TNFR1 shedding), although its sub-
cellular localization and role in the immune system had not been
recognized at that point [21–23]. ERAP1 is a 100 kDa,
monomeric, soluble zinc aminopeptidase that belongs to the M1
family of metallo-peptidases. ERAP1 is induced by interferon-c
and can degrade peptides 9–15 residues long. ERAP1 has been
found to greatly affect presentation of specific antigenic peptides
tested, as highlighted by cell based antigen presentation assays as
well as with the recent construction of an ERAP1
2/2 transgenic
mouse [24–27]. In those studies, ERAP1 deletion had complex
effects that varied depending on the epitope examined: the
presentation of some epitopes was down-regulated whereas the
presentation of others was up-regulated; some epitopes remained
unaffected. The molecular basis for these effects is currently
unclear. Two enzymatic properties of ERAP1 have been
recognized thus far that can help scientists understand its role in
antigen presentation. First, although human ERAP1 degrades
efficiently relatively long peptides (9–15 residues long) its activity
seems to dramatically decrease for peptides 8 residues and smaller
[15,16]. Second, human ERAP1 has been shown to degrade a
series of model peptides varying on their C-terminus, with
different rates for each peptide, demonstrating a preference for
hydrophobic amino acids at that position [16]. However, these
unique properties of ERAP1 are not enough to sufficiently explain
the enzyme’s complex role in antigen presentation.
N-terminally extended precursors of antigenic epitopes that are
transported into the ER consist of a very large variety of
sequences. To investigate the effect of the peptide sequence in
ERAP1 trimming we over-expressed the human enzyme in a
baculovirus driven insect cell expression system and used the
purified recombinant enzyme to screen collections of peptides for
degradation of their N-terminal residues by ERAP1. We found
that ERAP1 exhibited very strong preferences for specific amino
acids in several positions of the peptide substrate, particularly for
hydrophobic and positively charged side-chains. We demonstrate
trimming rate differences of up to 100-fold for single residue
replacements distal from the N-terminus and over 40,000-fold for
several replacements at once. To our knowledge no other
aminopeptidase has been described to have such strong prefer-
ences for residues distal to the N-terminus. Our results suggest a
complex molecular recognition between ERAP1 and its peptide-
substrate, spanning the full length of the peptide. The possible
repercussions of these substrate preferences in the understanding
of ERAP1’s role in antigen presentation are discussed.
Materials and Methods
Peptides
Peptides of the series XYWANATRSG [28], TXDNKTRAY,
TVXNKTRAY, TVDXNKTAY, TVDAXNKTY, TVNKTXRAY,
TVDNKTXAY [11], TVDNKTRYX,a n dT V D N K T R Y X [29]
with X being 8–10 different amino acids have been described.
Peptides were synthesized by Fmoc chemistry using an Abimed
Multiple Synthesizer AMS422 (Abimed, Langen, Germany). The
composition was confirmed by mass spectrometry. Peptides used for
the alanine scan were purchased by JPT peptide technologies, Berlin,
Germany. All other peptides were purchased by GenScript, New
Jersey, USA. Peptides were purified by HPLC and were .95% pure.
Baculovirus construction
Baculovirus carrying cDNA coding for human ERAP1 was
constructed according to the instructions of the Bac-to-BacH
Baculovirus Expression System (Invitrogen). Briefly, the pcDNA6/
myc-His-ERAP1 [16] plasmid was digested with EcoRI/PmeI and
ligated to a previously digested with EcoRI/StuI pFastBac plasmid.
The resulting pFastBac plasmid was used to transform competent
DH10Bac E.coli. The bacmid product of recombination in the
DH10Bac was isolated by standard DNA preparation methodology
and used to transfect SF9 insect cells to produce the recombinant
baculovirus. The baculovirus was harvested from the cell superna-
tant and its viral titer determined by plaque assay. Larger amounts
of virus were produced by infecting SF9 cell cultures and collecting
the supernatant after infection was established.
Protein expression and purification
Human recombinant ERAP1 was produced in Hi5 insect cells
grown in Excel405
TM serum free medium, after infection by
baculovirus carrying the ERAP1 gene with a C-terminal hexa-His
tag. The enzyme was secreted into the cell medium, which was
harvested by centrifugation (3000 rpm, 30 min, 4uC, GSA rotor)
in a Sorvall centrifuge. The cell supernatant was subjected to 3
rounds of buffer exchange (10 fold dilution each time) using a large
scale diafiltration apparatus versus 5 mM phosphate buffer at
pH 7 containing 100 mM NaCl. The supernatant was then
concentrated and its composition adjusted to 50 mM phosphate
(pH 8), 300 mM NaCl, 10 mM imidazole and immediately loaded
onto a HiTrap
TM chelating column (Qiagen) that was pre-loaded
with Ni(II)SO4. The column was washed with the same buffer
containing 20 mM imidazole and the protein was eluted using a
20 mM to 150 mM imidazole gradient. The resulting peak was
collected and dialyzed versus 10 mM HEPES buffer pH 8 and
then loaded on a MonoQ
TM column (Pharmacia) and eluted with
a 20 mM to 500 mM NaCl gradient. The resulting peak
exhibiting highest activity was collected and further purified on
a S200 size exclusion column (Pharmacia). The purified enzyme
was found to have comparable activity and digestive properties to
enzyme expressed previously in 293F cells [16] with regard to
fluorigenic dipeptide digestion and QLESIINFEKL peptide
digestion (data not shown).
Measurement of enzymatic activity by fluorescent
substrate
The aminopeptidase activity of the recombinant produced
ERAP1 was followed during the expression and purification steps
by the fluorescent signal produced upon digestion of the substrate
L-leucine 7-amido-4-methyl coumarin (Sigma-Aldrich). The same
assay was used to monitor the stability of the enzyme upon storage
and as a calibration assay for the analysis of enzymatic activity by
HPLC.
Measurement of enzymatic activity by analysis of peptide
products on reverse-phase HPLC
The digestion of model peptides by ERAP1 was followed by
analysis of peptide products of the digestion on a reverse phase C18
ERAP1 Substrate Specificity
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peptide was mixed in 50 mL total volume with 40 to 400 ng purified
recombinant enzyme in 20 mM Tris pH 8 buffer containing
100 mM NaCl. The mixture was incubated at 37uC for 30 min to
4 hrs. After incubation the reaction was stopped by the addition of
50 mL of 0.6% TFA and the sample centrifuged for 15 min at
15 000 g. 50 mL of the supernatant were subjected to HPLC
analysis. The reverse phase column was equilibrated in either
0.05% trifluoroacetic acid and 5% acetonitrile or 10 mM Sodium
Phosphate pH 6.8, 5% acetonitrile before the sample was injected.
The elution was done with a 5% to 40% acetonitrile gradient at
1 ml/min, while following the absorbance at 214 nm or 280 nm.
Typically, the decrease in peak surface area for a specific peptide
(identified by running control experiments or by LC-MS experi-
ments)upondigestionwithERAP1wasused toestimatetheamount
of peptide that was digested. In all cases, the decrease of the initial
peak resulted in the appearance of a new single product peak that
had a surface area equal to the surfaceareadecrease of the substrate
peak (measured from a control experiment in the absence of
enzyme). A typical chromatogram of peptide product analysis after
ERAP1 digestion is shown in Figure 1. Several experiments were
performed for each peptide tested to fine-tune the reaction
conditions (reaction time and amount of enzyme used) and to test
reproducibility of results. Each peptide series (varying at one
position) was tested in parallel to account for possible variability in
the reactions due to changes in enzyme activity upon storage and
from preparation to preparation.
Molecular modelling
Sequence alignment of ERAP1 and Tricorn Interacting Factor
F3 (TIFF3) was performed using ClustalW 1.83 [30]. Homology
models of ERAP1[58–948] were generated using Modeller 8.2[31]
using the 3 crystal structures of TIFF3 (PDB codes: 1Z1W and
1Z5H) as templates. The lowest energy model for each
conformation was further subjected to energy minimization in
vacuum with AMBER 8 and their stereochemistry was assessed
using PROCHECK [32,33]. Docking of the peptide LMAAFA-
KAF and LMAAKAKAF in the catalytic cleft of ERAP1 was
performed following the procedure described in [34]. Models were
analyzed using VMD 1.8.5 and electrostatic potential surfaces
were generated using the APBS and PME electrostatics packages
[35,36]. Visualization of the electrostatic potential was performed
with PyMol [37].
Results
ERAP1 trims the N-terminus of peptides with preference
for hydrophobic residues
ERAP1 has been characterized before as a leucine aminopep-
tidasebecause itpreferablydegrades dipeptide fluorigenicsubstrates
that have a leucine at their N-terminus [22]. However this strong
preference conflicts, to a certain extent, with the role of ERAP1 in
antigen processing, where it must trim peptides with a vast range of
sequences. To address the N-terminal specificity of ERAP1 when
degrading peptides we over-expressed human recombinant full-
length ERAP1 in insectcell suspension culture and used the purified
active enzyme in degradation assays in which we measured the
amount of trimming of the N-terminal residue of a panel of peptides
that variedonlyontheir N-terminus (Figure1 and 2).We found that
in agreement with the dipeptide digestion results, leucine was the
preferred N-terminal residue. Other hydrophobic residues, such as
methionine, phenylalanine and alanine were also digested reason-
ably fast. Non-optimal residues such as charged or hydrophilic in
nature, required larger (at least 10 times) amounts of ERAP1 for
their removal (data not shown). Overall, ERAP1 appears to indeed
act as a leucine aminopeptidase when degrading model peptides
although the digestion proceeds, albeit at a much slower rate, for
other residues as well.
Figure 1. Typical chromatogram of peptide product analysis
after ERAP1 digestion. Samples were analyzed by HPLC reverse
phase chromatography. 100 mM peptide with sequence FYWANATRSG
(written from N-terminus to C-terminus) was mixed with 40 ng of
ERAP1 and the mixture was incubated at 37uC. At different time points
a sample of the reaction was extracted and mixed with an equal volume
of 0.6% Trifluoroacetic acid (to stop the enzymatic reaction) and kept at
220uC until analysis. Solid line: Sample at zero time point, indicating the
elution of the undigested peptide (peak 1, confirmed by control runs of
peptide alone). Gray line: Sample after 1 hr of incubation. The surface
area of peak 1 is reduced indicating partial digestion of peptide. A new
peak can be seen (peak 2) corresponding to the peptide product of the
reaction YWANATRSG. The reduction of the surface area of peak 1 is
equal to the surface of peak 2 and is typically used to calculate the
percent consumption of the peptide substrate.
doi:10.1371/journal.pone.0003658.g001
Figure 2. N-terminal specificity of decapeptide trimming by
ERAP1. All peptides are based on the same template varying in their N-
terminus (indicated as X in the sequence below the graph). 100 mMo f
each peptide was incubated with 40 ng of ERAP1 at 37uC and the
reaction products analyzed as in figure 1. A representative experiment
is shown here. Peptides carrying hydrophobic residues at their N-
termini were trimmed fastest, whereas peptides carrying charged (R, K
or E) or hydrophilic (T) residues in their N-termini were more resistant to
cleavage by ERAP1.
doi:10.1371/journal.pone.0003658.g002
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To investigate whether internal residues of the peptide are
important for N-terminal trimming by ERAP1 we used a collection
of 10mer peptides based on the sequence LYWANATRSG, where
one internal residue at a time is replaced by alanine. In every case
the removal of the optimal N-terminal residue type (leucine) by
ERAP1 was followed by reverse-phase HPLC. Substituting alanine
in most positions affected N-terminal trimming by ERAP1 to a
moderate degree. Replacement of the arginine residue at position 8
(relative to the N-terminus of the peptide) resulted to a peptide that
was surprisingly resistant to N-terminal trimming by ERAP1
(Figure 3A). Specifically, the N-terminus of the peptide LYWANA-
TASG was trimmed with a rate of 0.3560.02 pmol/mg ERAP16
sec, whereas the control peptide LYWANATRSG was trimmed
with a rate 30.467.1 pmol/mgE R A P 1 6sec, a rate almost 100 fold
higher (Figure 3B). This finding indicates that internal positions of
the peptide substrate can be just as important in determining N-
terminal trimming as the nature of the N-terminus.
Trimming of the N-terminus of a collection of 9mer
peptides by ERAP1 is affected by the internal sequence
of the peptide
To systematically test the role of internal residues of peptide
substrates on the rate of N-terminus trimming by ERAP1 we used
the active recombinant enzyme in degradation assays with an
already available collection of more than 70 synthetic model
peptides (Figure 4). This peptide collection has been used before in
the investigation of the specificity of the peptide transporter TAP
[11]. All peptides were 9mers and had a threonine residue at their
N-termini. Degradation of the N-terminus of each peptide was
followed by HPLC as described in the experimental section. Each
peptide series (varying at one position) was analyzed in parallel to
account for variability in enzyme activity between preparations
and during storage. Several experiments were performed for each
peptide series to fine-tune the reaction conditions (reaction time
and amount of enzyme used) and to test reproducibility of results.
One representative set is shown in Figure 4. The efficiency of
ERAP1 trimming was strongly affected by the nature of the
residue at several positions in the peptide sequence (Figure 4).
Specifically, positions 2, 5 and 7 (with position 1 defined as the N-
terminal residue of the peptide) were found to be most important
for the sensitivity of the peptide to ERAP1 degradation. Some
degree of residue preference was also evident for positions 4, 8 and
9. Positions 3 and 6 showed the least specificity although some
small effects were present. Residue preferences were only seen for
hydrophobic and positively charged residues. No preference was
seen for negative or hydrophilic residues in any of the positions.
The presence of a negatively charged residue (glutamate)
anywhere in the peptide sequence seemed to negatively affect
the peptide’s degradation by ERAP1 regardless of its location in
the peptide sequence (to a lesser extent for position 3). The same
general observation seems to apply for glycine and proline
residues. Certain positions showed a very strong preference for
particular amino-acid side-chains. Position 2 for example,
exhibited a strong preference for a methionine residue whereas
position 7 showed a very strong preference for positively charged
residues (lysine or arginine). Interestingly, position 5 showed a
strong preference for either a positive charge or an aromatic
residue (phenylalanine). This ‘‘dual’’ preference was observed in
other positions also (position 9) and may indicate alternative
binding configurations for the two peptides (refer to the molecular
modeling section below). Overall, strong sequence preferences
were clearly evident from this library screen even without a more
detailed kinetic study. To simplify screening, a single time point
analysis was used in Figure 4 and as a result some of the differences
seen there could be under-estimations of the kinetic differences,
especially for reactions where the substrate consumption is over
50%. However, several of the preferences are so strong that are
clearly evident even from a single time-point analysis.
To validate the library results we designed two model peptides
based on the preferences observed in Figure 4. The trimming of
the N-terminal leucine residue of peptide LVAFKARKF (peptide
K) and LTAEEAVET (peptide E) by ERAP1 was evaluated by
Figure 3. A. Alanine scan of N-terminal trimming of the same 10mer peptide by ERAP1. Peptide variants of the sequence LYWANATRSG designed so
that one internal position at a time is sequentially replaced by alanine were analyzed for their susceptibility to N-terminus trimming by 40 ng of
ERAP1. Error bars represent the variability between three separate experiments performed in parallel. Less than 1% trimming was detected for
peptide LYWANATASG under the conditions of the experiment presented. B. Rates of N-terminus trimming by ERAP1 for peptides LYWANATRSG and
LYWANATASG. Substitution of the arginine residue at position 8 by alanine leads to reduction of trimming rates by almost 100 fold. Rates are plotted
in logarithmic scale for clarity.
doi:10.1371/journal.pone.0003658.g003
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positions, carrying amino acids that were found to be preferred by
ERAP1 based on the 9mer library screen. In contrast peptide E,
carries one of the least preferred amino acids for each of these
positions. Both peptides have the same N-terminal residue,
allowing the examination of preferences distal to the N-terminus
Figure 4. Trimming of the N-terminal residue of a library of 9mer peptides by ERAP1. Peptide series vary in one position per collection
(indicated on the top of each panel; varying amino acid is shown as X) and are presented from left to right and from top to bottom for positions 2 to
9 from the N-terminus. The y-axis indicates percentage of substrate (peptide) depleted based on analysis by HPLC. The x-axis indicates the amino acid
in the particular peptide in each collection, ordered by hydrophobicity (from hydrophilic amino-acids to hydrophobic). Note that for some collections
the effect of substituting for particular amino acids is much higher than in others. One representative experiment is presented for each peptide set.
doi:10.1371/journal.pone.0003658.g004
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ERAP1 even at mM enzyme concentrations whereas peptide K
was trimmed efficiently even at nM enzyme concentrations
(Figure 5, panels A and B). To investigate this further, we
measured the trimming rate of the N-terminal residue of the two
peptides by ERAP1. ERAP1 trimmed peptide K with a rate of
57.863.8 pmol/mg6sec and peptide E with a rate of
0.001460.0002 pmol/mg6sec a difference of more than 40,000
fold (Figure 5C). This impressive difference suggests that single
positional side-chain preferences by ERAP1 can synergize to
larger sequence preferences.
Our results for ERAP1 sequence preferences are in sharp
contrast to the results obtained with the same library for TAP
transport preferences where only the C-terminal residue was found
to be important [11]. Such specificity effects originating from side-
chains distal from the scissile N-terminal peptide bond are, to our
knowledge and up to date, unique to this aminopeptidase and have
only been partially observed before as differential substrate
specificity depending on the C-terminus of an unrelated series of
peptides [16]. Our results suggest that ERAP1 recognizes
sequence (amino-acid side chains) in the peptide substrate it
degrades. The ramifications of this finding to our understanding of
antigenic peptide generation and destruction are discussed below.
Homology modelling of ERAP1 based on the structure of
TIFF3 reveals an extended putative peptide-binding site
that has a strong negative electrostatic potential
To form an atomic level framework for understanding the
sequence specificity effects observed during screening model
peptides we constructed a homology model for ERAP1 based on
the structure of the sequence related enzyme Tricorn Interacting
Factor F3 (TIFF3). In the absence of a high-resolution structure of
ERAP1, TIFF3 is the closest homolog to ERAP1 for which a high-
resolution crystal structure is available [38]. By virtue of a BLAST
homology search, ERAP1 displays 32% identity (residues 63–665)
with TIFF3, 25% identity (residues 180–484) with the human
leukotriene A4 hydrolase (LTA4H); and 25% identity (residues
180–489) with aminopeptidase N from Escherichia Coli (pepN).
Full sequence alignment of ERAP1 and TIFF3 using ClustalW
1.83 exhibits 28% identity (residues 58–948) with three major gaps
(grey regions). However, ERAP1[280–486] that comprises the major
part of the catalytic domain displays 43% sequence identity to the
equivalent domain of TIFF3 with 84% identity at the core of the
zinc-binding domain (residues 352–382). The alignment of
ERAP1 with TIFF3 is shown in Figure 6.
The ERAP1 models we generated exhibit structural character-
isticsthatappearhighlyrelevant tothepeptidelibraryscreenresults.
A central wide and deep cavity leads to the active site Zn(II) and is
an obvious candidate to accommodate the peptide substrate
(Figure 7, top panel). The cavity is large enough to accommodate
a 9mer or even larger peptide (Figure 7, bottom panel). The cavity
carries a strongly negative electrostatic potential but at the same
time containsseveralhydrophobicpockets.The equivalentregionof
TIFF3 displays no such electrostatic potential distribution (data not
shown). Based on the crystallographic analysis of TIFF3 there are 3
different molecular models that slightly vary in their inter-domain
configuration. Depending on the TIFF3 model used for the
construction of the ERAP1 homology model the opening to the
aforementioned central cavity varies slightly in size; however the
gross features (electrostatic potential and size) were found to be
virtually unchanged (data not shown).
To gain insight on how peptide-substrates could interact with
the enzyme we employed docking calculations of model peptides
into the homology model of ERAP1. The model peptides were
Figure 5. Validation of library screen. The most pronounced
preferences found from the library screen in figure 4 were used to
design two peptides that would be expected to be a bad and a good
ERAP1 substrate respectively. Trimming of the N-terminal leucine of
peptides E (sequence LTAEEAVET) and K (sequence LVAFKARKF) was
followed by HPLC. The two peptides differ at 6 internal positions,
carrying at those positions the amino acids that were found to be the
least and the most preferred by ERAP1 respectively. Panel A,5 0mM
peptide E was incubated with 800 nM ERAP1 for 1 hr at 37uC and the
digestion products analyzed by reverse-phase chromatography. Pep-
tide E was completely resistant to trimming under those conditions.
Panel B 50 mM peptide K was incubated with 1 nM ERAP1 for 1 hr at
37uC and the digestion products analyzed by reverse-phase chroma-
tography. Peptide K was efficiently trimmed (arrow points at product
peak) under these conditions. Panel C, trimming rates for peptides E
and K by ERAP1, average of 3–4 experiments. The y-axis is logarithmic
for better visualization of the difference. ERAP1 trims peptide K more
than 40,000 times faster than it trims peptide E.
doi:10.1371/journal.pone.0003658.g005
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PLoS ONE | www.plosone.org 6 November 2008 | Volume 3 | Issue 11 | e3658Figure 6. Sequence alignment of ERAP1 with Tricorn Interacting Factor F3 (TIFF3). The two proteins have a 28% sequence identity in the
amino acid range of 58–948 and up to 43% sequence identity in the range of 280–486 that is the major part of the catalytic domain (underlined).
Alignment reveals the presence of 3 major gaps (in grey).
doi:10.1371/journal.pone.0003658.g006
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adjacent to the active site Zn(II) (Figure 7). In every case, the whole
length of the model peptide was easily accommodated and was
found to form an extended network of interactions with ERAP1’s
putative binding cavity. However, due to the relatively low
homology between ERAP1 and TIFF3 that can lead to uncertain-
ties in the ERAP1 model, the found interactions between the
peptide and ERAP1 were not further evaluated. It should be noted
though that interactions between the positively charged residues in
the C-terminal moietyof the model peptides and negatively charged
residues in ERAP1’s putative binding cavity potentially explain the
strong substrate specificity effect seen for positively charged side
chains. Conversely, the negative electrostatic potential of the cavity
would be expected to hinderthe approachandbindingofnegatively
charged peptides (especially with charges in the C-terminal moiety)
an observation that could explain the negative effect of glutamate
residues in peptide degradation. Overall, the ERAP1 homology
model seems to provide an appropriate framework for at least a
gross understanding of the basis of substrate specificity of ERAP1. A
high-resolution structure of ERAP1 would be required for more
reliable modelling calculations.
Sequence effects on trimming of longer peptides
carrying N- or C-terminal extensions of the same core
sequence
Many of the antigenic peptide precursors that are sent to the ER
through the action of TAP are peptides up to 13–15 amino acid
[39]. To test whether strong internal sequence related effects are
also evident when ERAP1 is trimming peptides of such lengths and
alsotogaininsight on the mode ofmolecular recognitionofpeptides
by ERAP1 we measured the N-terminal trimming of 3 peptides
based on the sequence of the ovalbumin antigenic epitope
SIINFEKL (Figure 8). A control peptide with the sequence
LSIINFEKL was used that we expected (based on previously
published results on closely related sequences[19]) to be trimmed
efficiently by ERAP1 leading to the removal of the N-terminal
leucine residue. Two more peptides were tested: a peptide with the
sequence LSIINFEKLAAAL and one with the sequence LAAAL-
SIINFEKL, both based on the same internal template LSIINFEKL
but with C- and N-terminal alanine extensions respectively. We
designed the extensions to contain alanine residues since alanine
lacks an extended side chain that may offer extra interactions with
the binding site of the enzyme and complicate this analysis. Since it
has been established that both the N- and C- termini of the peptide
are important for determining the rate of trimming by ERAP1, we
designed all 3 peptides to carry the same N and C terminal residue.
The peptide LSIINFEKL was trimmed efficiently by ERAP1
with a rate of 19.663.3 pmol/mg ERAP16sec (Figure 8A).
Similarly the peptide with sequence LSIINFEKLAAAL (a C-
terminally extended version of LSIINFEKL) was trimmed just as
efficiently with a rate of 22.465.8 pmol/mg ERAP16sec
(Figure 8B). In contrast, the peptide LAAALSIINFEKL (an N-
terminally extended version of LSIINFEKL) was trimmed very
poorly by ERAP1 (0.3460.13 pmol/mg ERAP16sec) and when
incubated under identical conditions as the other two peptides, it
was not trimmed at all (Figure 8C). Figure 8D shows a graphical
representation of the trimming rates on a logarithmic scale for
clarity. Notice how the trimming rate was essentially identical for
LSIINFEKL and LSIINFEKLAAAL but about 100 fold smaller
for LAAALSIINFEKL. These results clearly highlight how the
internal sequence of the peptide can greatly affect N-terminus
trimming rate by ERAP1. Furthermore, the similarity in trimming
rates between LSIINFEKL and the C-terminally extended version
LSIINFEKLAAAL, suggests that both substrates are recognized in
a similar fashion by the enzyme and that ERAP1 substrate
recognition occurs in reference to the N-terminus of the peptide.
Generality of sequence preferences
Both the alanine scan in Figure 3 and the library screen in
Figure 4 revealed a strong preference for a positively charged
residue at position 8 relative to the N-terminus of the peptide. To
test whether such a preference is more general we measured the
trimming rate of two model antigenic peptide precursors based on
epitopes of the MHCI molecule H-K
b, namely LSIINFEKL and
LVNVDYSKL (Figure 9). Both peptides carry identical N- and C-
termini, as well as a lysine residue at position 8 relative to the N-
terminus. Both peptides were efficiently trimmed by ERAP1,
resulting to the mature antigenic epitope. In both cases
substitution of the position 8 lysine residue by an alanine lead to
a marked decrease in trimming rate by ERAP1 by 8–10 fold
(Figure 9). This rate change is consistent with the decrease in
Figure 7. Homology model of ERAP1 based on the TIFF3
structure. Top panel: The model is displayed in surface representation
and coloured by electrostatic potential (red indicates negative
electrostatic potential, blue indicates positive electrostatic potential).
Notice the highly negatively charged (red) wide groove in the middle of
the molecule adjacent to the catalytic Zn(II). The model peptide (of the
sequence LMAAFAKAF in yellow) designed based on the library results
to represent a near optimal substrate was docked in the active site so
that the scissile amino-terminal peptide bond is positioned adjacent to
the catalytic site Zn(II). Bottom panel, detail view of docked peptide in
postulated binding site; the obstructing part of the protein has been
removed to allow easier visualization of the peptide. The predicted
location of the catalytic Zn(II) is indicated as a cyan sphere. Electrostatic
potentials were calculated by the PME electrostatics add-on of VMD
1.8.5 and picture created using Pymol 0.99.
doi:10.1371/journal.pone.0003658.g007
ERAP1 Substrate Specificity
PLoS ONE | www.plosone.org 8 November 2008 | Volume 3 | Issue 11 | e3658trimming for the series TVDKNTRXY in Figure 4 when a lysine
is compared to an alanine. Furthermore, it is consistent with the
effect seen for the 10mer in Figure 3, although the change in rate
was more pronounced in that case. Overall, we demonstrate that
eradication of a positive charge at position 8 of four unrelated
peptide sequences leads to a marked reduction in trimming by
ERAP1, suggesting that this effect might be more general.
Discussion
In this study we used collections of model peptides to systematically
study the effects of peptide sequence in the degradation of its N-
terminus by ERAP1. It should be noted that previous workwith other
aminopeptidases has indicated strong preferences only for the N-
terminal residue of the peptide as well as faster trimming for smaller
peptides [16]. In contrast, ERAP1 trims long peptides better than
short ones and its trimming rate can be also affected by the nature of
the C-terminus of the peptide [16]. We find here that the unique
properties of ERAP1 extend to strong internal sequence specificity
requirements for peptide substrate trimming. Negatively charged
side-chains on the peptide seem to make it a worse substrate for
ERAP1 as would be predicted from the negative electrostatic
potential of ERAP1’s putative peptide-binding site (Figure 7). In
contrast, we find strong preference for positively charged and
hydrophobic residues for several positions in the peptide-substrate.
These effects, taken together, suggest an extended molecular
recognition throughout the whole length of the peptide by ERAP1.
Molecular mechanism of ERAP1 peptide trimming
The striking properties of ERAP1 compared to known amino-
peptidases (length and sequence specificity distal to the scissile bond)
can only be understood in terms of unique structural features of this
enzyme. In the absence of a high-resolution crystal structure we
constructed a homology model using the structure of the related
aminopeptidase TIFF3. Although the model is of limited use for any
high-resolution structural conclusions, we anticipate that at least the
gross structural features of the protein will be reasonably accurate.
Analysis of the electrostatic potential distribution of the ERAP1
modelrevealedawidecentralcavitywithastrongnegativepotential.
This cavity is large enough to accommodate model peptides in
orientations that position their N-terminal scissile peptide bond in
close proximity to the catalytic Zn(II) atom (Figure 7). The
electrostatic potential of the cavity can easily explain why model
peptides that carry negative charges are poorer substrates for the
enzyme as well as the preference for positive charges at several
positions. Docking calculations with model peptides yielded low
energy conformations with several potential side chain interactions
between the peptide side-chains and amino acids in the cavity of
ERAP1. It is conceivable that interactions between such a presumed
cavity and peptide substrates are responsible for the peptide
specificity effects of ERAP1. Additionally, this cavity is large enough
to accommodate even larger peptides (particularly since the C-
terminus of the peptide can extend outwards towards the solvent)
with their N-terminus located adjacent to the catalytic Zn
++.T h i s
mode of recognition is consistent with our results that demonstrated
similar trimming kinetics between a model peptide and its C-
terminal extended version and very different trimming kinetics
Figure 8. Trimming of the N-terminal leucine of N- and C-
extended versions of LSIINFEKL peptide. Panels A–C, typical C18
chromatograms comparing the trimming for LSIINFEKL and the C- and
N-terminal extended versions LSIINFEKLAAAL and LAAALSIINFEKL. In
each panel two chromatograms are shown, the top one in the absence
of enzyme and the bottom in the presence of 40 ng ERAP1. All
incubations were done for 1 hr at 37uC. Black arrows indicate new
peaks detected after incubation with the enzyme. Under these
conditions LSIINFEKL and LSIINFEKLAAAL are trimmed about to the
same extent and LAAALSIINFEKL is resistant to any trimming. Panel D,
ERAP1 trimming rates calculated as the average of 3 to 5 experiments.
Because of the large difference between trimming rates the y-axis is
logarithmic for better visualization.
doi:10.1371/journal.pone.0003658.g008
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We therefore suggest that the substrate preferences we demonstrate
in this study arise from specific molecular interactions between the
peptide and an extended peptide binding site that lies adjacent to
ERAP1’s Zn(II) catalytic site.
Generality of trimming preferences
Since all enzymatic activity comparisons were performed within
eachpeptidecollectionourresultsaremostreadilygeneralizedinthat
context;i.e.substitutionofapositivelychargedaminoacid(likelysine)
at position 8 for an uncharged one (like alanine) wouldbe predicted to
Figure 9. Substitution of a lysine residue at position 8 of two model 9mer H2-K
b epitope precursors leads to a marked decrease of
N-terminus trimming by ERAP1 in vitro. Panels A and B, peptides LSIINFEKL and the variant LSIINFEAL (both at 50 mM) were incubated with
7.8 nM of ERAP1 for 1 hr at 37uC and the products analyzed by RP-HPLC. The product of the digestions, either SIINFEKL or SIINFEAL is marked on the
chromatogram by an arrow. Panel C, trimming rates for excision of the N-terminus of peptide LSIINFEKL and LSIINFEAL by ERAP1, average of 3
separate experiments. Panels D and E, peptides LVNVDYSKL and the variant LVNVDYSAL (both at 50 mM) were incubated with 15.6 nM of ERAP1 for
1h ra t3 7 uC and the products analyzed by RP-HPLC. The product of the digestions, either VNVDYSKL or VNVDYSAL is marked on the chromatogram
by an arrow. Panel F, trimming rates for excision of the N-terminus of peptides LVNVDYSKL and LVNVDYSAL by ERAP1, average of 3 separate
experiments. Note that in both cases, substituting an alanine for the lysine at position 8, leads to a decrease of N-terminus trimming rate by about 8–
10 fold.
doi:10.1371/journal.pone.0003658.g009
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generality of our observations is supported by the fact that we find
internal sequence effects in several unrelated peptide sequences of
different lengths (10mer in Figure 3, 9mers in Figure 4, 13mers in
Figure 8 and 9mers in Figure 9). In addition, the strong effect seen in
N-terminus trimming when the positively charged residue at position
8 of the peptide LYWANATRSG (Figure 3) is substituted by alanine
is consistent with the preference for positively charged residues at the
same position in the peptide series TVDKNTRXY (Figure 4). The
same effect is seen when the single positively charged residue is
substituted by alanine in the model precursors of natural occurring
antigenic epitopes LSIINFEKL and LVNVDYSKL (Figure 9),
suggesting that this preference for positive charges might be more
general.Furthermore, the sequenceLSIINFEKLAAALcompared to
the sequence LAAALSIINFEKL would be predicted to be preferred
due to residues at positions 6 (phenylalanine versus serine;
phenylalanine is found to be preferred over the serine homolog
threonine in the library in Figure 4), position 8 (lysine versus
isoleucine, lysine is preferred over the isoleucine homolog valine in
the library) and position 9 (leucine versus asparagine; the leucine
homolog valine is preferred over the asparagine homolog glutamine
in the library). Due to the limited residues tested in the library no clear
conclusion can be reached for the remaining positions. However,
every single position for which a conclusion can be reached, favors
LSIINFEKLAAAL over LAAALSIINFEKL. Possible synergy be-
tween the preferred residues in LSIINFEKLAAAL can potentially
explain the 100-fold faster trimming rate. Whether the cumulative
specificityeffectfrommorethanonepositioninthepeptideisadditive
or synergistic is a potentially important question for substrate
prediction that requires further experimentation to answer. In any
case, the strong internal sequence specificity effects observed in our
study, in combination with the structural features of the enzyme’s
peptide-binding site (i.e. negative electrostatic potential, Figure 7),
suggestthattheERAP1trimmingpreferencesarenotrestrictedtothe
limited sequence templates tested here, but might be more general.
However, further analysis with peptide collections based on multiple
unrelated sequence templates may be necessary to establish clear
substrate sequence recognition motifs.
Antigenic peptide generation and ERAP1 substrate
preferences
Several publications during the last few years have highlighted the
importance of ERAP1 in generating peptides for antigen presenta-
tion. Its sub-cellular localization, induction by interferon-c and
peptide substrate length preference all fit well with a specific role in
preparing peptides before loading onto nascent MHC class I
molecules [14–16,19]. Furthermore, antigenic peptide presentation
assays have indicated that ERAP1 can have complex effects on
antigenic epitopes depending on the nature of the epitope tested
[14,19]. Recent work by four independent laboratories has examined
the effect of deletion of the ERAP1 gene in mice and concluded
strong, epitope-dependent effects in antigenic presentation [24–
26,40]. Generally the effect of ERAP1 activity in vivo seems to be
complex; down-regulation or over-expression of ERAP1 levels have
different and often opposite results for different epitopes, as well as
negligible results for others. One factor that differentiates between
epitopes is their sequence as well as the sequence of their extended
precursors. If ERAP1, as suggested by our data, trims peptides at
dramatically different rates depending on their internal sequence and
this also applies inside the cell, it would not be surprising that ERAP1
down-regulation would lead to different effects depending on the
epitope studied. Furthermore, most MHCI epitopes are 9mers and
we find that ERAP1 can trim about half of the 9mers tested in
Figure 4, depending on sequence. Such an activity would effectively
destroy the antigenicepitope, again ina sequencedependent manner.
Down-regulation of ERAP1 activity would therefore be expected to
enhance the abundance of such epitopes. Overall, our findings
suggest that it is possible that ERAP1’s activity poses a bias in the
generated sequence of antigenic peptides by trimming antigenic
peptide precursors at very different rates depending on the precursor
sequence. It is not inconceivable that this bias can be related to the
editing properties attributed to the enzyme [27,41]. Although more
detailed work is needed to fully understand this effect, it is possible
that the unique substrate specificity of ERAP1 is one of the reasons
behind the complex effects seen with epitopes of different sequences
in deletion experiments.
In summary, in this study we have characterized the substrate
specificity of ERAP1, an important enzyme in the generation of
antigenic peptides that has received a great deal of attention by the
scientific community the last few years. Our results demonstrate
that ERAP1 has strong internal sequence preferences for the
peptide-substrate that can potentially strongly affect peptide
trimming rates. These preferences are possibly mediated by a
unique for this aminopeptidase, extended peptide binding site. We
therefore propose that the whole sequence and not just the N-
terminus or the C-terminus of the antigenic peptide precursor, is
the determining factor in the efficiency of generation or even
destruction of an antigenic peptide by ERAP1.
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